{"id":69955,"date":"2026-07-14T15:07:42","date_gmt":"2026-07-14T07:07:42","guid":{"rendered":"https:\/\/flcube.com\/?p=69955"},"modified":"2026-07-14T15:07:43","modified_gmt":"2026-07-14T07:07:43","slug":"haisco-pharmaceutical-secures-nmpa-ind-acceptance-for-hsk60002-tablets-in-inflammatory-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69955","title":{"rendered":"Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Haisco Pharmaceutical Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002653:SHE\">SHE: 002653<\/a>) announced that the <strong>Investigational New Drug (IND) application<\/strong> for its innovative drug <strong>HSK60002 tablets<\/strong> has been accepted by China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>, paving the way for clinical trials in <strong>inflammatory diseases<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>IND acceptance (clinical trial authorization)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>HSK60002 tablets \u2013 Category 1 chemical drug<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Inflammatory diseases (broad therapeutic area)<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Category 1 chemical drug (China&#8217;s highest innovation tier)<\/td><\/tr><tr><td><strong>Development Status<\/strong><\/td><td>Preclinical completed, Phase I preparation initiated<\/td><\/tr><tr><td><strong>Intellectual Property<\/strong><\/td><td>Proprietary compound with independent IP rights<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>14 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-preclinical-data\" class=\"wp-block-heading\">Drug Profile &amp; Preclinical Data<\/h2>\n\n\n\n<h3 id=\"h-hsk60002-novel-oral-anti-inflammatory-agent\" class=\"wp-block-heading\">HSK60002 \u2013 Novel Oral Anti-Inflammatory Agent<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Orally administered small-molecule formulation<\/li>\n\n\n\n<li><strong>Innovation Status:<\/strong> Independently developed by Haisco with proprietary intellectual property<\/li>\n\n\n\n<li><strong>Regulatory Classification:<\/strong> Category 1 chemical drug (novel active ingredient not previously marketed in China)<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong> Well-defined pathway targeting inflammatory processes (specific target undisclosed)<\/li>\n\n\n\n<li><strong>Preclinical Results:<\/strong> Demonstrated significant pharmacodynamic activity in relevant animal models of inflammation<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-therapeutic-area-context\" class=\"wp-block-heading\">Therapeutic Area Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Inflammatory Diseases Market:<\/strong> Encompasses conditions including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and other autoimmune disorders<\/li>\n\n\n\n<li><strong>Global Market Size:<\/strong> Estimated at $120+ billion annually with continued growth driven by aging populations and improved diagnosis<\/li>\n\n\n\n<li><strong>Unmet Needs:<\/strong> Despite existing biologics and small molecules, significant patient populations remain refractory to current therapies or experience intolerable side effects<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Strategic Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Pipeline Diversification<\/strong><\/td><td>Expands Haisco&#8217;s portfolio beyond neurology into high-value inflammatory disease space<\/td><\/tr><tr><td><strong>Innovation Validation<\/strong><\/td><td>Category 1 designation reinforces Haisco&#8217;s R&amp;D capabilities and commitment to novel drug discovery<\/td><\/tr><tr><td><strong>Commercial Potential<\/strong><\/td><td>Oral small-molecule format offers advantages in manufacturing scalability, distribution, and patient compliance compared to biologics<\/td><\/tr><tr><td><strong>Global Development Pathway<\/strong><\/td><td>Success in China could support international clinical development given universal nature of inflammatory pathways<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td>Enters crowded but premium market segment requiring clear differentiation through efficacy, safety, or dosing advantages<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral vs. Biologic Competition:<\/strong> Small molecules compete with established biologics (TNF inhibitors, IL-17\/23 inhibitors) but offer cost advantages and convenient administration<\/li>\n\n\n\n<li><strong>Chinese Innovation Focus:<\/strong> Part of broader trend of Chinese pharmaceutical companies developing novel mechanisms rather than biosimilars or me-too compounds<\/li>\n\n\n\n<li><strong>Regulatory Environment:<\/strong> NMPA&#8217;s acceptance reflects streamlined review processes for high-quality innovative candidates<\/li>\n\n\n\n<li><strong>Investment Thesis:<\/strong> Category 1 drugs command premium valuations and represent de-risked assets for potential partnerships<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The inflammatory disease space continues to represent one of pharmaceutical&#8217;s most attractive therapeutic areas due to chronic treatment requirements, premium pricing, and large addressable patient populations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development, regulatory pathways, and commercial potential for HSK60002. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836fHSK60002\u7247IND\u7533\u8bf7\u300a\u53d7\u7406\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836fHSK60002\u7247IND\u7533\u8bf7\u300a\u53d7\u7406\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-2934aca3-6687-42d9-948c-cf642b45801c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836fHSK60002\u7247IND\u7533\u8bf7\u300a\u53d7\u7406\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\">\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836fHSK60002\u7247IND\u7533\u8bf7\u300a\u53d7\u7406\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836fHSK60002\u7247IND\u7533\u8bf7\u300a\u53d7\u7406\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2934aca3-6687-42d9-948c-cf642b45801c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the Investigational New Drug (IND) application&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[90,139,929],"class_list":["post-69955","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-filings","tag-haisco-pharmaceutical","tag-she-002653"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the Investigational New Drug (IND) application for its innovative drug HSK60002 tablets has been accepted by China&#039;s National Medical Products Administration (NMPA), paving the way for clinical trials in inflammatory diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69955\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases\" \/>\n<meta property=\"og:description\" content=\"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the Investigational New Drug (IND) application for its innovative drug HSK60002 tablets has been accepted by China&#039;s National Medical Products Administration (NMPA), paving the way for clinical trials in inflammatory diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69955\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-14T07:07:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-14T07:07:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69955#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69955\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases\",\"datePublished\":\"2026-07-14T07:07:42+00:00\",\"dateModified\":\"2026-07-14T07:07:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69955\"},\"wordCount\":456,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial filings\",\"Haisco Pharmaceutical\",\"SHE: 002653\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69955#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69955\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69955\",\"name\":\"Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-14T07:07:42+00:00\",\"dateModified\":\"2026-07-14T07:07:43+00:00\",\"description\":\"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the Investigational New Drug (IND) application for its innovative drug HSK60002 tablets has been accepted by China's National Medical Products Administration (NMPA), paving the way for clinical trials in inflammatory diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69955#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69955\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69955#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the Investigational New Drug (IND) application for its innovative drug HSK60002 tablets has been accepted by China's National Medical Products Administration (NMPA), paving the way for clinical trials in inflammatory diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69955","og_locale":"en_US","og_type":"article","og_title":"Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases","og_description":"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the Investigational New Drug (IND) application for its innovative drug HSK60002 tablets has been accepted by China's National Medical Products Administration (NMPA), paving the way for clinical trials in inflammatory diseases.","og_url":"https:\/\/flcube.com\/?p=69955","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-14T07:07:42+00:00","article_modified_time":"2026-07-14T07:07:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69955#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69955"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases","datePublished":"2026-07-14T07:07:42+00:00","dateModified":"2026-07-14T07:07:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69955"},"wordCount":456,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial filings","Haisco Pharmaceutical","SHE: 002653"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69955#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69955","url":"https:\/\/flcube.com\/?p=69955","name":"Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-14T07:07:42+00:00","dateModified":"2026-07-14T07:07:43+00:00","description":"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the Investigational New Drug (IND) application for its innovative drug HSK60002 tablets has been accepted by China's National Medical Products Administration (NMPA), paving the way for clinical trials in inflammatory diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69955#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69955"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69955#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69955"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69955\/revisions"}],"predecessor-version":[{"id":69957,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69955\/revisions\/69957"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}